Featured Research

from universities, journals, and other organizations

Antibody-Targeted Chemotherapy-Induced Remission And Stem-Cell Transplantation Prolong Disease-Free Survival For Leukemia Patients

Date:
December 14, 2000
Source:
Fred Hutchinson Cancer Research Center
Summary:
Patients with acute myeloid leukemia (AML) who achieve remission with the antibody-targeted chemotherapy agent Mylotarg™ (gemtuzumab ozogamicin for injection) have prolonged disease-free survival following stem cell transplantation according to research presented at the annual meeting of the American Society of Hematology (ASH).

SEATTLE - December 4, 2000 - Patients with acute myeloid leukemia (AML) who achieve remission with the antibody-targeted chemotherapy agent Mylotarg™ (gemtuzumab ozogamicin for injection) have prolonged disease-free survival following stem cell transplantation according to research presented today at the annual meeting of the American Society of Hematology (ASH). These early data, from clinical studies conducted at the Fred Hutchinson Cancer Research Center and other centers, suggest that pre-transplant therapy with Mylotarg can enable patients to receive curative therapy in the form of hematopoietic stem cell transplantation.

AML is among the most serious forms of adult leukemia, with a relatively high fatality rate. It is an aggressive form of cancer in which certain white blood cells become cancerous and rapidly accumulate in the bone marrow, preventing normal marrow from growing and functioning properly. Most AML patients undergo intensive chemotherapy to achieve complete remission, and some also must undergo bone marrow transplants. Because standard chemotherapy drugs to treat AML are non-specific - destroying normal as well as malignant cells - patients who receive the therapy tend to become very sick.

"Intensive chemotherapy is a real challenge for most patients. Mylotarg is different because it has enabled us to achieve remissions with less severe side effects," said Eric Sievers, M.D., of Fred Hutchinson Cancer Research Center. "Our study shows that if a patient achieves remission with Mylotarg and subsequently receives a hematopoietic stem cell transplant, they have an excellent chance of prolonged disease-free survival."

Twenty-two patients with AML in first relapse who achieved remissions with Mylotarg received hematopoietic stem cell transplantation (HSCT). Eleven patients received allogeneic and 11 received autologous hematopoietic stem cell transplants. A majority of patients were alive without leukemia one year after the transplant. At the time of data cutoff, the median relapse-free survival for the 22 patients was 17.4 months after transplant.

"We believe that hematopoietic stem cell transplants appear to cause fewer complications than bone marrow transplants and that Mylotarg appears to cause fewer severe side effects than standard chemotherapy," Sievers continued. "This study shows us that we can offer our high-risk patients tolerable treatment that may prolong their chances of survival."

Researchers at the Fred Hutchinson Cancer Research Center, and eleven other leading leukemia centers, including University of Chicago Medical Center, MD Anderson Cancer Center, The University of Pennsylvania Cancer Center, Wayne State University, and the City of Hope Medical Center, are working with Wyeth-Ayerst Laboratories and Celltech Chiroscience to study Mylotarg, an antibody-drug conjugate that targets chemotherapy treatment to leukemia cells. Mylotarg was approved by the U.S. Food and Drug Administration on May 18, 2000, and is manufactured by Wyeth-Ayerst Laboratories.

The Fred Hutchinson Cancer Research Center is an independent, non-profit research institution dedicated to the development and advancement of biomedical technology to eliminate cancer and other potentially fatal diseases. Recognized internationally for its pioneering work in bone marrow transplantation, the Center has four scientific divisions collaborating to form a unique environment for conducting basic and applied science. One of 35 National Cancer Institute-designated comprehensive cancer centers in the country, it is the only one in the Northwest. Visit the Hutchinson Center web site for more information at http://www.fhcrc.org.


Story Source:

The above story is based on materials provided by Fred Hutchinson Cancer Research Center. Note: Materials may be edited for content and length.


Cite This Page:

Fred Hutchinson Cancer Research Center. "Antibody-Targeted Chemotherapy-Induced Remission And Stem-Cell Transplantation Prolong Disease-Free Survival For Leukemia Patients." ScienceDaily. ScienceDaily, 14 December 2000. <www.sciencedaily.com/releases/2000/12/001204072823.htm>.
Fred Hutchinson Cancer Research Center. (2000, December 14). Antibody-Targeted Chemotherapy-Induced Remission And Stem-Cell Transplantation Prolong Disease-Free Survival For Leukemia Patients. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2000/12/001204072823.htm
Fred Hutchinson Cancer Research Center. "Antibody-Targeted Chemotherapy-Induced Remission And Stem-Cell Transplantation Prolong Disease-Free Survival For Leukemia Patients." ScienceDaily. www.sciencedaily.com/releases/2000/12/001204072823.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins